Cardinal Salute Inc. plans to test the use of drones to expedite the delivery of pills, inhalers and other items to US pharmacies, a move that the healthcare supply distributor says could also reduce transportation costs for urgent shipments. subscribe to the newsletter The logistic relationship Top news and insights into the world of logistics, …
Cardinal Health will test the delivery of drones to pharmacies Read More »
If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have less stock market capitalizations than they have in cash. “The market is saying that a quarter of these companies are literally worth nothing,” says Jefferies biotech analyst Michael Yee, …
If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have less stock market capitalizations than they have in cash. “The market is saying that a quarter of these companies are literally worth nothing,” says Jefferies biotech analyst Michael Yee, …
If you want to know how much investors hate the biotech industry right now, consider this simple statistic: More than 25% of small biotech companies have lower market capitalizations than they have in cash. “The market is saying that a quarter of these companies are literally worth nothing,” says Jefferies biotech analyst Michael Yee, who …
Text size About 80 biotechnologies in Russell 2000 have market capitalizations below last year’s inclusion limit. Time to dream The biotech acquisitions were supposed to revive the sector, but despite the biggest deal reached this year, this was yet another bad week, very bad for equities. The end may come soon, painfully but positively, according …
It’s another bad week for biotech stocks. Relief could come next month. Read More »
Even in the risky biotech sector, investors are looking for slightly less risk. Time to dream Text size It would be difficult to overstate the poor performance of biotech stocks this year. Even as investors rushed into defensive healthcare stocks, the SPDR S&P Biotech listed fund (ticker: XBI) fell 37% in 2022 at close of …
Biotech stocks are having a terrible year. These 10 are still winning. Read More »
Photo: Getty Images / iStockphoto We are rationing health care. The reason isn’t a shortage of beds, medications, ventilators, or surgical suites. This is a shortage of health personnel. As with other parts of the American economy, healthcare has pushed its workforce to the limit. Doctors, nurses, administrators, respiratory therapists and others have been in …
Text size Even in the risky biotech sector, investors are looking for slightly less risk. Time to dream It would be difficult to overstate the poor performance of biotech stocks this year. Even as investors rushed into defensive healthcare stocks, the SPDR S & P Biotech ETF (ticker: XBI) was down 37.3% in 2022 at …
Biotech stocks are having a terrible year. These 10 are still winning. Read More »
Previous versions of this story featured the image of a KN95 mask instead of an N95 mask. The image has been updated. Less than a week after the Biden administration announced it plans to release 400 million free N95 masks in drugstores and health centers across the country, some pharmacies have already received their shipments …
Free N95 Masks Launch In Pharmacy Like Walgreens This Week – How To Get Them Read More »
Text size Barron’s said in late March that the long-term arguments for biotech stocks are strong. Time to dream For biotech stocks this year, April was indeed the cruelest month. The SPDR S&P Biotech listed fund (ticker: XBI) fell 17.9% in April, bringing the total decline for 2022 to 34.1%. Over the past 12 months, …
Biotech stocks are still in decline. The near-term outlook is bleak. Read More »
